Drug firms slack on DTC guidelines

Share this article:
Two reports issued by PhRMA indicate that while signatories to its DTC guidelines are generally following them, they mostly have a long way to go.

The first report contained observations from four volunteer health professionals who agreed to monitor TV and print DTC ads last year. While they reached no conclusions regarding drug manufacturers' compliance with the guiding principles, they offered these general impressions:
A few DTC campaigns ran ads that educated consumers about the relevant medical condition before launching branded ads, but most provided info about the condition. The most educationally effective ad they saw promoted an Rx medicine in the context of raising consumer awareness of a condition and prompting contact with a physician.

DTC ads can prompt patient dialogue but because of a lack of access to information, many doctors feel unprepared to address patient issues about a new medicine when a DTC ad breaks.

The second report was PhRMA's Office of Accountability survey of companies who
received 458 comments from the public about DTC ads during the second half of 2006. Some comments expressed distaste for the creative concepts chosen, and concern that “inappropriate” ads are still being aired when minors are likely to see them.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...